Association between persistent smoking after a diagnosis of heart failure and adverse health outcomes: A systematic review and meta-analysis

Youn-Jung Son¹, Hyeon-Ju Lee²

ABSTRACT

INTRODUCTION Heart failure (HF) is associated with increased mortality worldwide. Adverse health outcomes in HF are commonly attributed to poor adherence to self-care, including smoking cessation. Smoking is the major modifiable risk factor for HF. Patients have been observed to continue smoking even after diagnosis with HF. Despite the possible association between persistent smoking and adverse health outcomes among HF populations, no consensus has been reached. We aimed to review the literature to determine the association between smoking status after HF diagnosis and adverse health outcomes.

METHODS A systematic literature search was performed in PubMed, PsycINFO, Web of Science, and Embase. Hand searching was also performed. In total, 9 articles (n=70461) were included in the review for meta-analysis, including seven cohort studies and two cross-sectional studies. Quality was assessed using the modified version of the Newcastle–Ottawa Scale.

RESULTS Approximately 16% of HF patients continued smoking after HF diagnosis. Persistent smoking increased the hazard ratio (HR) of mortality by 38.4% (HR=1.384; 95% CI: 1.139–1.681) and readmission by 44.8% (HR=1.448; 95% CI: 1.086–1.930). Our review also found that persistent smoking was associated with poor health status, ventricular tachycardia, and arterial stiffness.

CONCLUSIONS This review highlights the importance of assessment for any history of smoking before and after HF diagnosis. There is a need for smoking cessation programs to be established as crucial components of care for patients with HF. More studies are needed to investigate the possible mechanisms underlying relations among smoking patterns and health consequences.
WHO reported that 10% of all deaths due to CVD can be attributed to smoking1. Importantly, persistent smoking after HF diagnosis has been shown to worsen the long-term outcomes in HF and to reduce the efficacy of HF treatment10. Specifically, smoking not only increases the risk of coronary artery disease, a major cause of HF, but also increases systolic and diastolic blood pressure and oxidative stress. Furthermore, smoking can lead to vascular inflammation, worsening endothelial function and renal function, all of which have been implicated in the pathophysiology of HF11.

Previous studies have reported that despite the recommendation to quit smoking after CVD diagnosis, many patients continued smoking, and their smoking behaviors varied extensively10,12. A study by Lim et al.13 reported that approximately 50% of smokers continued smoking even after CVD events. Another study also reported that about 16% of participants with HF were currently smoking14. A meta-analysis of 14 studies showed that the smoking cessation rates after ischemic heart disease ranged from 7% to 63%15. Some studies have suggested that poor adherence to HF treatment, including smoking cessation, increases the risk of adverse health outcomes15,16.

Despite this possible association between persistent smoking and adverse health outcomes among HF populations, to our knowledge, there has been no consensus on the magnitude of smoking-related morbidity and mortality in patients with HF12,13. A recent review reported that more cardiovascular events in heavier smokers have failed to find a significant negative correlation between smoking habits and cardiovascular risk10. Furthermore, few studies have systematically reviewed the literature regarding this relationship. Therefore, the purpose of this study was to examine the association between persistent smoking and the risk of adverse health outcomes in patients with HF, through a critical appraisal of the literature.

METHODS
Search strategies
The current study was performed according to The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines17. We used the Patient, Interest (or Intervention), Comparison, and Outcomes (PICO) strategy for the construction of the research question of this review: ‘Does persistent smoking (Interest) influence adverse health outcomes (Outcomes) among HF patients (Patients)?’. The ‘C’ element in PICO was not used since the objective of this review did not include clinical trials. The search strategy used was: [smoking OR tobacco OR nicotine OR cigarette smoking) AND (heart failure OR cardiac failure OR heart decompensation OR congestive heart failure OR chronic heart failure) AND (risk OR adverse outcome OR morbidity OR mortality OR readmission OR emergency room visit OR heart rate variability OR heart attack OR ischemic heart disease)].

To identify all relevant articles, published up to 30 June 2019, we conducted an extensive electronic literature search in PubMed (from 1946), PsycINFO (from 1806), Web of Science (from 1900), and Embase (from 1947). Gray literature was searched for additional potentially relevant articles. Hand search was also performed.

Study selection
Two independent reviewers screened the titles and abstracts of each included study. At this stage, the reviewers extracted possibly all relevant studies. To be included, studies and peer-reviewed articles needed to be: 1) published in English, and 2) original research using any observational study design (e.g. cross-sectional or cohort) that reported on smoking status in patients with HF as a primary study group. Studies excluded were: 1) intervention studies, reviews, conference abstracts, and letters; 2) studies with no outcome; and 3) studies with insufficient data. Disagreements on eligibility were reconciled by the reviewers. Because no primary data were to be collected, approval from an ethics committee was not required (Figure 1).

Outcome measures
Outcome measures included mortality, readmission, length of stay, and incidence of adverse health outcomes; specifically, pathological changes such as artery calcification or self-reported health status (Table 1).

Data extraction
Items extracted as characteristics of the included studies comprised: first author’s surname, publication year, study location, study design, follow-up period,
number of study participants, number of persistent smokers, smoking assessment, smoking status identified, outcomes, adjusted variables, and main findings (Table 1).

This study also presented the characteristics of the HF patients included in this review. Patient characteristics included: sex, mean age, mean HF duration, HF identified, mean left ventricular ejection fraction (LVEF), mean B-type natriuretic peptide (BNP), and New York Heart Association (NYHA) functional class. In case of disagreement between the two reviewers, consensus was reached after discussion (Table 2).

**Table 1. Characteristics of studies included**

| Authors (publication year) / location | Study design | Follow-Up period (months) | Sample size (n) | Persistent smokers (%) | Smoking assessment | Smoking status identified |
|--------------------------------------|--------------|----------------------------|----------------|------------------------|--------------------|--------------------------|
| Evangelista et al. (2000)/ USA       | Retrospective | 24                         | 753            | 336 (44.6)             | Medical records    | Never/ former/ current smokers |
| Suskin et al. (2001)/ USA, Canada, Belgium | Prospective | 41                         | 6704           | 1562 (23.3)            | NA                 | Never/ former/ current smokers |
| Fonarow et al. (2008)/USA            | Prospective  | 22                         | 48612          | 7743 (15.9)            | Medical records    | Never/ current smokers    |
| Conard et al. (2009)/ USA            | Cross-sectional | 12                        | 537            | 84 (15.6)              | Self-reported      | Never/ former/ current smokers |
| Javaheri et al. (2012)/USA           | Prospective  | NA                         | 87             | 15 (17.2)              | NA                 | Non or former/ current smokers |
| Graham et al. (2014)/USA            | Retrospective | NA                         | 2043           | 352 (17.2)             | Self-reported      | Never/ former/ current smokers |
| Li et al. (2017)/China              | Cross-sectional | 26                        | 354            | 39 (11.1)              | Medical records    | Non or former/ current smokers |
| Eriksson et al. (2018)/ Sweden      | Prospective  | 36                         | 9654           | 1005 (10.4)            | Medical records    | Never/ former/ current smokers |
| Sandesara et al. (2018)/ USA        | Retrospective | 33                         | 1717           | 116 (6.8)              | Self-reported      | Never/ former/ current smokers |

**Assessment of methodological quality**

The Newcastle–Ottawa scale (NOS) for cross-sectional and cohort studies was used to assess the quality of all included studies. The NOS system consists of 8 items with three subscales: selection of studies, comparability of studies, and the ascertainment of the exposure/outcome of interest. Each item on the scale scored one point. Comparability scored up to two points by adjusting for the topic of interest. Specifically, the maximum score for each study was nine points, with studies scores from five to nine considered of satisfactory quality. All studies were independently rated by two reviewers to assess the quality. Any disagreements in quality assessment were resolved via discussion until consensus was reached.

Table 3 shows the scores regarding the validity of included studies. We considered that the studies with NOS scores of five or greater indicated moderate to high quality studies.

**Data synthesis**

We investigated how smoking status affected health in patients diagnosed with HF. These estimates were combined using meta-analysis with a random-effects model to derive summary hazard ratio (HR) estimates by outcome.

We used a random-effects model because of the presumed heterogeneity between the studies. Heterogeneity was analyzed using $I^2$ with its 95% confidence interval (CI) and Q statistics (statistical
significance was set at p<0.05). The Comprehensive Meta-Analysis software (version 3.0; Biostat, Englewood, NJ, USA) was used to calculate the pooled estimates and forest plots.

RESULTS
Overview of the included studies
We initially confirmed a total of 518 studies that met our search criteria. After performing a title and abstract review, 365 studies were excluded resulting in 153 studies that underwent full-text review. Finally, nine studies (five cohort, two cross-sectional, and two recent cohort) were included in the review (Figure 1).

Table 1 summarizes the articles and their findings. The follow-up period ranged from 12 to 41 months and the sample size ranged from 87 to 4861 with a total of 70461, of which, 11252 (16%) continued to smoke after HF diagnosis. Smoking status was categorized as current smokers and non-smokers including former or never smokers. Information on smoking history was obtained via self-reported questionnaires and medical records. Using Newcastle–Ottawa’s quality tools, most of the studies were considered to be of good quality, while one study was evaluated to have fair quality. The scores ranged from 5 to 9 (Table 3).
Characteristics of HF patients included in this review

The demographic data of the HF patients in the studies are given in Table 2. Fifty-four per cent of the samples were men. The mean age range of the study participants was 59.4 to 77.3 years. The duration of HF was reported in two studies as 5.73 years and more than 6 months, respectively. The severity of HF was verified by LVEF and BNP values, and NYHA functional class. In six studies, the LVEF was <40%. Mean BNP was reported in three studies and ranged from 138.0 to 827.3. The NYHA functional classification was reported in seven studies.

The impact of smoking on adverse health outcomes

In the present study, persistent smoking showed association with mortality (n=5), readmission (n=3), and disease-specific health status (n=1), ventricular tachycardia (n=1), arterial stiffness (n=1), cognitive

---

**Table 2. Characteristics of HF patients in the included studies**

| Authors (publication year) | Sex (% | Mean age or range (years) | Mean HF duration (years) | HF identified | Mean LVEF or range (%) | Mean BNP or range (pg/mL) | NYHA functional class (%) |
|---------------------------|------------------|--------------------------|--------------------------|---------------|------------------------|--------------------------|--------------------------|
| Evangelista et al. (2000)20 | M: 98.8, F: 1.2 | 69 (33–99) | 5.73 | Medical records (ICD-9 codes) | NA | NA | III/IV = 13.9/0.8 |
| Suskin et al. (2001)21 | M: 84.6, F: 15.4 | 59.4 | NA | Medical records (LVEF, NYHA) | 25.3 | NA | III/IV = 13.9/0.8 |
| Fonarow et al. (2008)22 | M: 48.0, F: 52.0 | 73.1 | NA | Medical records (LVEF) | 39 | 827.3 | NA |
| Conard et al. (2009)14 | M: 76.2, F: 23.8 | NA | NA | Medical records (LVEF, NYHA class, BNP) | <40 | 359.4 | III/IV = 41.3/5.7 |
| Javaheri et al. (2012)23 | Male only | 64 | NA | Medical records (LVEF, NYHA class) | 25 | NA | III = 15.5 |
| Graham et al. (2014)24 | M: 80.0, F: 20.0 | 60.8 | NA | Medical records (LVEF, NYHA class) | ≤35 | NA | III/IV = 29.2/1.2 |
| Li et al. (2017)25 | M: 47.5, F: 52.5 | 68.2 | NA | Medical records (LVEF) | 55.3 | 138 (96–152) | NA |
| Eriksson et al. (2018)26 | M: 53.8, F: 46.2 | 77.3 | >6 months | Medical records (LVEF, NYHA class) | ≥40 | NA | III/IV = 29.4/1.4 |
| Sandesara et al. (2018)27 | M: 50.0, F: 50.0 | 71 | NA | Medical records (NYHA class) | NA | NA | III & IV = 35.4 |

HF: heart failure; LVEF: left ventricular ejection fraction, BNP: B-type natriuretic peptide, NYHA: New York Heart Association, ICD: international classification of diseases, NA: not available.

---

**Table 3. Quality assessment of the included studies**

| Study | Selection | Comparability | Outcome | Total score |
|-------|-----------|---------------|---------|-------------|
| Evangelista et al. (2000)20 | 4 | 1 | 2 | 7 |
| Suskin et al. (2001)21 | 4 | 1 | 3 | 8 |
| Fonarow et al. (2008)22 | 4 | 1 | 2 | 7 |
| Conard et al. (2009)14 | 2 | 2 | 3 | 7 |
| Javaheri et al. (2012)23 | 2 | 1 | 2 | 5 |
| Graham et al. (2014)24 | 3 | 1 | 2 | 6 |
| Li et al. (2017)25 | 4 | 2 | 3 | 9 |
| Eriksson et al. (2018)26 | 3 | 1 | 3 | 7 |
| Sandesara et al. (2018)27 | 3 | 1 | 2 | 6 |
function (n=1), and length of stay (n=1) after the diagnosis of HF.

**Mortality**

Five studies provided data on mortality among those who continued smoking after HF diagnosis. Three of the studies used prospective cohort study design to assess mortality\(^{21,22,26}\), one used a retrospective cohort study design\(^{27}\), while the other used a cross-sectional design\(^{14}\). One was conducted in Sweden, while four reported data from the same population in the USA.

Three of the included studies were meta-analyses\(^{14,21,27}\). The risk of mortality was greater in current smokers than in non-smokers (combined HR=1.384; 95% CI: 1.139–1.681; n=8958). The pooled results showed low heterogeneity (I\(^2\)=5.5%; p=0.347) (Figure 2).

Subgroup analysis revealed a higher mortality risk ratio of never smokers versus current smokers of 1.820 (95% CI: 1.191–2.782; 1 study, n=1717) than that of non-smokers versus current smokers (1.402; 95% CI: 0.955–2.060; 2 studies, n=7241). Although two studies noted that continuous smoking after HF diagnosis was independently associated with mortality, they provided no statistical data\(^{22,26}\).

**Readmission rates**

Three studies reported on the association between readmission and persistent smoking after HF diagnosis. Two of such studies used retrospective cohort study design to assess readmission\(^{20,27}\) while the other was a prospective cohort study\(^{21}\). All studies were conducted in the US. The risk of readmission was greater in current smokers than in non-smokers (combined HR=1.448; 95% CI: 1.086–1.930; n=7457). The pooled results showed moderate heterogeneity (I\(^2\)=57.14%; p=0.097) (Figure 3).

Subgroup analysis revealed a higher readmission risk ratio of never smokers versus current smokers of 1.680 (95% CI: 1.081–2.612; one study, n=1717) than non-smokers versus current smokers (1.402; 95% CI: 0.955–2.060; 2 studies, n=7457).

**Other adverse health outcomes**

One cross-sectional study conducted in the US examined the disease-specific health status depending on the smoking status after HF diagnosis\(^{14}\). Statistically significant differences in the disease-specific health status were observed between the smoker and non-smoker groups in terms of physical function, symptoms, social function, self-efficacy, and quality of life (F=3.47; p=0.03; n=537). In particular, the disease-specific health status was lower in current smokers than in never smokers (p=0.01) or former smokers (p=0.02). One prospective cohort study conducted in the US examined the incidence of...
ventricular tachycardia (VT) during sleep depending on the smoking status after HF diagnosis\textsuperscript{23}. The incidence of VT was greater in current smokers than in non-smokers (OR=9.96; 95\% CI: 1.93–51.48; n=87). One cross-sectional study conducted in China examined the incidence of arterial stiffness depending on the smoking status after HF diagnosis\textsuperscript{25}. Current smoking was an independent determinant of arterial stiffness (β=0.121; p=0.013; n=354). One retrospective cohort study conducted in the US examined the cognitive function depending on the smoking status after HF diagnosis\textsuperscript{24}. Both current (β=0.321; p=0.016; n=2043) and former smokers (β=0.204; p=0.041) had higher cognitive function than never smokers. One prospective cohort study conducted in the US examined the length of stay in the hospital, depending on the smoking status after HF diagnosis\textsuperscript{22}. Smokers had similar length of stay in the hospital compared to non-smokers (relative risk, RR=0.37; 95\% CI: 0.94–0.99; n=48612).

**DISCUSSION**

Despite the strong association of smoking with cardiovascular disease and adverse events, little is known about the impact of persistent smoking after a HF diagnosis on patient outcomes. In this review, we found that persistent smoking after HF diagnosis, compared with non-smoking (former or never smoking), increased the risk of adverse health outcomes. In particular, our main finding was that current smokers, who continued smoking after HF diagnosis, were more susceptible to mortality and readmissions than non-smokers.

Our meta-analysis demonstrated that mortality was the most frequently examined variable out of the seven types of adverse health outcomes associated with smoking status. Furthermore, persistent smokers showed higher mortality than non-smokers. However, we could not verify whether the higher mortality among persistent smokers was primarily ascribable to the functional deterioration of the cardiovascular system or to other causes, given that most data used in the studies indicated ‘all-cause mortality’ as the cause of death. Specifically, chemical constituents of smoke have high oxidant and inflammatory power that can directly induce endothelial damage and potentiate inflammatory response\textsuperscript{28-30}. Namely, cigarette smoking can promote atherosclerosis by its effects on lipid profile\textsuperscript{35,31}. Moreover, according to one study\textsuperscript{22}, nicotine along with carbon monoxide and oxidative stress induce fibrosis at different cardiac sites; thus, generating a structural remodeling that may favor cardiac arrhythmia. For these reasons, the damaged cardiovascular system induces myocardial systolic and diastolic dysfunction through smoking, thus aggravating HF symptoms\textsuperscript{21}, which can result in death. Consequently, further studies are necessary to completely understand the exact mechanisms underlying the vascular damage induced by smoking. Such knowledge can help healthcare providers to educate active or heavy smokers after a HF diagnosis against smoking.

In previous studies, tobacco smoking was associated with higher risk of cognitive decline. These associations are thought to be caused mainly by smoking-related damage, which develops during cardiovascular and respiratory processes in the brain\textsuperscript{33,34}. However, in a study in which cognitive function was reported depending on the smoking status, current smokers were found to have higher cognitive function than never smokers\textsuperscript{24}. This may be explained by the fact that a cognitive function decline is associated not only with smoking but also with other factors, such as age, hemoglobin level, and body mass index\textsuperscript{35,36}. These factors act as confounding variables, and there is a need to adjust for them. Moreover, only one of the studies analyzed in this systematic review examined the association between cognitive function and smoking status after HF diagnosis, and the validity of its findings will have to be verified by additional research. In one study that examined the length of stay in the hospital in relation to smoking status, persistent smokers and non-smokers showed similar lengths of stay\textsuperscript{22}. This study noted that the sudden smoking cessation after hospitalization might have resulted in the improved health status. Although the average length of stay in the hospital reported in this study was 4 days, too short a period of smoking cessation to improve health. Taken together, HF patients who are smoking at diagnosis may benefit from counseling regarding the harms of continued smoking after a diagnosis of HF, as one way to improve quit rates. Secondhand smoke exposure is related to increased risk of CVD and ischemic heart disease\textsuperscript{37,38}. Thus, smoke-free policies within hospitals can help persistent smokers to attempt to quit smoking.
In our review, of 70461 participants, 11252 (16%) from nine studies continued smoking after HF diagnosis. Similar percentages were found in previous studies for diseases associated with smoking: 14.1% of 1700 patients with CVD\textsuperscript{13}; 17.6% of 5185 patients diagnosed with cancer\textsuperscript{39}; and 17% of 893 patients with lung cancer\textsuperscript{40}. Most of the patients diagnosed with HF undergo interventions designed to prevent the aggravation of HF. Such interventions include smoking cessation, low-salt diet, abstinence from drinking, regular exercise, and management of risk factors such as hypertension, diabetes, and hyperlipidemia\textsuperscript{41}. The finding of this study showing that 16% of patients with HF failed to quit smoking highlights the need of customized health education for the patients by identifying the causes of persistent smoking and negative attitudes towards health-promoting behaviors.

Our review of the studies included, found that the follow-up period (12–41 months) was not sufficiently long to verify the adverse health outcomes for persistent smoking after a HF diagnosis. A cohort study should be performed to clearly indicate the temporal sequence between exposure and outcome, or with a long follow-up period in case of a low incidence rate\textsuperscript{42}. In particular, a lifestyle variable like smoking requires a study design providing sufficient follow-up for the target outcome, given its long-term negative health consequences. Furthermore, the smoking intensity, such as cumulative smoking in pack-years, number of cigarettes smoked per day, and duration of smoking, was not sufficiently examined. In previous studies, dose effect association between pack-years of exposure and HF risk was observed\textsuperscript{43}. Furthermore, current smokers’ risk of HF increased as their daily tobacco consumption increased\textsuperscript{44}. That is, since smoking affects the cardiovascular system to a greater or lesser extent depending on smoking intensity, strategies for smoking reduction will have to be developed by investigating the threshold smoking intensity for exacerbating HF. For HF diagnosis, medical records (objective data) were used in all studies, while NYHA functional class, LVEF, and BNP, were used to verify the severity of HF. NYHA functional class is a subjective measure useful for determining the motor skills and symptoms of patients with HF and widely used for monitoring patients with HF\textsuperscript{45}. NYHA functional class and LVEF were well documented in 77.8% of the included studies, to describe the subjective and objective characteristics of the patients with HF. When the level of LVEF is ≥40%, the ventricle volume increases, and pressure overload must be monitored by additionally checking the increase in BNP\textsuperscript{46,47}. Of the two studies reporting LVEF ≥40% in this systematic review, only one investigated BNP. To ensure a clear explication of the association between smoking status after HF diagnosis and adverse health outcomes, NYHA, BNP and LVEF will have to be clearly determined as the diagnostic criteria for HF.

Strengths and limitations
Our systematic review has several strengths. We performed a comprehensive review of various databases to identify the health outcomes reported to be caused by persistent smoking after HF diagnosis. All papers were quality assessed using a robust method. Also, five of the seven adverse health outcomes – mortality, readmission, ventricular tachycardia, arterial stiffness, length of stay – were collected through medical records and can be regarded as objective information, which reduces the risk of bias. We provided a detailed description of HF-related patient characteristics by identifying the related objective (LVEF, BNP) and subjective (NYHA functional class) symptoms. Most of all, this study found evidence that suggests negative effects with persistent smoking, on the various health outcomes. There is a need for further studies to identify mechanisms or pathways between smoking and adverse health outcomes in HF patients. Awareness among healthcare providers of the adverse effects of smoking on the progression of HF should be increased.

This study has some limitations. In the present observational study, we found it difficult to control for relative confounding directly. We were also not able to investigate problems with natural confounding in the original studies. Most of the studies included did not categorize the type of HF, such as HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). Previous studies showed that risk factors could be different between HFpEF and HFrEF\textsuperscript{46,47}. Specifically, the smoker status has been associated with structural changes with increase in left ventricular mass compared with non-smokers\textsuperscript{10}. With regard to this phenomenon, this study
was not able to explain in detail the harmful impact, between HFpEF and HFrEF. We did not provide sufficient information regarding the characteristics of patients with HF because only two studies reported the duration of HF. Since smoking status was self-reported or evaluated based on medical records, it might not have provided adequate objective measures compared with biochemical tests. Most of these studies were conducted in the US (77.8%), hence the results of the present study lack generalizability to other populations.

CONCLUSIONS

Our study showed that approximately 16% of smokers continued smoking even after HF diagnosis. This supports the need to assess patients’ smoking status during outpatient follow-up visits. Importantly, our review identified that adverse health outcomes were more common in persistent smokers after HF diagnosis than in non-smoker patients. Healthcare professionals should create awareness regarding the harm of continued smoking in HF patients. Particularly, patients willing to try to reduce or stop smoking should be encouraged. Further studies are needed to explore underlying reasons why HF patients continue to smoke after a HF diagnosis, in order to develop patient-centered smoking cessation strategies. Furthermore, the causal relationships between persistent smoking and various aspects of adverse health outcomes can be determined with a large and culturally diverse HF population.

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Published May 17, 2017. Accessed June 20, 2019.

2. Albano MG, Jourdain P, De Andrade V, Domenke A, Desmos M, d’Ivernois Jean-François. Therapeutic patient education in heart failure: do studies provide sufficient information about the educational programme? Arch Cardiovasc Dis. 2014;107(5):328-339. doi:10.1016/j.acvd.2013.12.002

3. Inamdar AA, Inamdar AC. Heart Failure: Diagnosis, Management and Utilization. J Clin Med. 2016;5(7). doi:10.3390/jcm5070062

4. Moser DK, Dickson V, Jaarsma T, Lee C, Stromberg A, Riegel B. Role of self-care in the patient with heart failure. Curr Cardiol Rep. 2012;14(3):265-275. doi:10.1007/s11886-012-0267-9

5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128

6. Wang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors in relation to heart failure among Finnish men and women. Circ Heart Fail. 2011;4(5):607-612. doi:10.1161/CIRCHEARTFAILURE.111.962589

7. Agha G, Loucks EB, Tinker LF, et al. Healthy lifestyle and decreasing risk of heart failure in women: the Women’s Health Initiative observational study. J Am Coll Cardiol. 2014;64(17):1777-1785. doi:10.1016/j.jacc.2014.07.981

8. Del Gobbo LC, Kalantarian S, Imamura F, et al. Contribution of major lifestyle risk factors for incident heart failure in older adults: The Cardiovascular Health Study. JACC Heart Fail. 2015;3(7):520-528. doi:10.1016/j.jchf.2015.02.009

9. Fleg JL. Healthy lifestyle and risk of heart failure: An ounce of prevention well worth the effort. Circ Heart Fail. 2016;9(4):e003155. doi:10.1161/CIRCHEARTFAILURE.116.003155

10. Ambrose JA, Barus RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am Coll Cardiol. 2004;43(10):1731-1737. doi:10.1016/j.jacc.2003.12.047

11. Kamimura D, Cain LR, Mentz RJ, et al. Cigarette smoking and incident heart failure. Circulation. 2018;137(24):2572-2582. doi:10.1161/CIRCULATIONAHA.117.031912

12. Kim HE, Song YM, Kim BK, Park YS, Kim MH. Factors associated with persistent smoking after the diagnosis of cardiovascular disease. Korean J Fam Med. 2013;34(3):160-168. doi:10.4082/kjfm.2013.34.3.160

13. Lim YK, Shin DW, Kim HS, et al. Persistent smoking after a cardiovascular event: A nationwide retrospective study in Korea. PLoS One. 2017;12:e0186872. doi:10.1371/journal.pone.0186872

14. Conard MW, Haddock CK, Poston WS, Spertus JA. The impact of smoking status on the health status of heart failure patients. Congest Heart Fail. 2009;15(2):82-86. doi:10.1111/j.1751-7133.2009.00053.x

15. Rahman MA, Edward KL, Montgomery L, McEvedy S, Wilson A, Worrall-Carter L. Is there any gender difference for smoking persistence or relapse following diagnosis or hospitalization for coronary heart disease? Evidence from a systematic review and meta-analysis. Nicotine Tob Res. 2016;18(6):1399-1407. doi:10.1093/ntr/ntv222

16. Prochaska JJ, Benowitz NL. Smoking cessation and the cardiovascular patient. Curr Opin Cardiol. 2015;30:506-511. doi:10.1097/HCO.0000000000000204

17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-2012.
doi:10.1001/jama.283.15.2008

18. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Published April, 2016. Accessed June 20, 2019.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. doi:10.1136/bmj.327.7414.557
20. Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among Veterans. Am J Cardiol. 2000;86(12):1339-1342. doi:10.1016/s0002-9149(00)01238-8
21. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37(6):1677-1682. doi:10.1016/s0735-1097(01)01195-0
22. Fonarow GC, Abraham WT, Albert NM, et al. A smoker’s paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J. 2008;29(16):1983-1991. doi:10.1093/eurheartj/ehn210
23. Javaheri S, Shukla R, Wexler L. Association of smoking, sleep apnea, and plasma alkalosis with nocturnal ventricular arrhythmias in men with systolic heart failure. Chest. 2012;141(6):1449-1456. doi:10.1378/chest.11-1724
24. Graham S, Ye S, Qian M, et al. Cognitive function in ambulatory patients with systolic heart failure: Insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. PLoS One. 2014;9:1-16. doi:10.1371/journal.pone.0113447
25. Li L, Hu B, Gong S, Yu Y, Yan J. Age and cigarette smoking modulate the relationship between pulmonary function and arterial stiffness in heart failure. Medicine. 2017;96(10):e6262. doi:10.1097/MD.0000000000006262
26. Eriksson B, Wandell, P, Dahlstrom U, Nasman P, Lund LH, Edner M. Comorbidities, risk factors and outcomes in patients with heart failure and an ejection fraction of more than or equal to 40% in primary care-and hospital care-based outpatient clinics. Scand J Prim Health Care. 2018;36(2):207-215. doi:10.1080/02813432.2018.1459654
27. Sandesara PB, Samman-Tahan A, Topel M, Venkatesh S, O’Neal WT. Effect of cigarette smoking on risk for adverse events in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2018;122(3):400-404. doi:10.1016/j.amjcard.2018.04.016
28. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6-14. doi:10.1161/01.cir.76.1.6
29. Tsuchiya M, Asada A, Kasahara E, Sato EF, Shindo M, Inoue M. Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation. 2002;105(10):1155-1157. doi:10.1161/01.hc1002.105935
30. Rabinowitz BD, Thorp K, Huber GL, Abellman WH. Acute hemodynamic effects of cigarette smoking in man assessed by systolic time intervals and echocardiography. Circulation. 1979;60(4):752-760. doi:10.1161/01.cir.60.4.752
31. Gambardella J, Sardu C, Sacra C, Giudice CD, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis. 2017;257:242-245. doi:10.1016/j.atherosclerosis.2016.01.010
32. D’Alessandro A, Boeckelmann I, Hammwhoner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol. 2011;19:297-305. doi:10.1177/1741826711411738
33. Anesty KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166(4):367-378. doi:10.1093/aje/kwm116
34. Karama S, Ducharme S, Corley J, et al. Cigarette smoking and thinning of the brain’s cortex. Mol Psychiatry. 2015;20:778-785. doi:10.1038/mp.2014.187
35. Tereckci HM, Kucukardali Y, Onem Y, et al. Relationship between anemia and cognitive function in elderly people. Eur J Intern Med. 2010;21(2):87-90. doi:10.1016/j.ejim.2009.12.005
36. Cronk BB, Johnson DK, Burns JM. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2010;24(2):126-130. doi:10.1097/WAD.0b013e3181a66bf3f
37. Glantz SA, Parmley WW. Even a little secondhand smoke is dangerous. JAMA. 2001;286:462-463. doi:10.1001/jama.286.4.462
38. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111:2684-2698. doi:10.1161/circulationaha.104.492215
39. Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. Smoking at diagnosis and survival in cancer patients. Int J Cancer. 2013;132(2):401-410. doi:10.1002/ijc.27617
40. Daniel M, Keefe FJ, Lyna P, et al. Persistent Smoking and Dementia: Findings from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. JAMA. 2001;286:462-463. doi:10.1001/jama.286.4.462
41. Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(2):115-126. doi:10.1002/ejhf.hcq219
42. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. J Am Coll Cardiol. 1992;20(2):287-294. doi:10.1016/0735-1097(92)90092-2
43. Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, et al. Cigarette smoking exposure and heart failure
risk in older adults: The Health, aging, and body composition study. Am Heart J. 2012;164(2):236-242. doi:10.1016/j.ahj.2012.05.013

44. Feodoroff M, Harjutsalo V, Forsblom C, Groop PH. Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes. Diabetologia. 2018;61(12):2580-2589. doi:10.1007/s00125-018-4725-9

45. Holland R, Rechel B, Stepień K, Harvey I, Brooksby I. Patients’ self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail. 2010;16(2):150-156. doi:10.1016/j.cardfail.2009.08.010

46. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635-641. doi:10.1016/j.jacc.2003.09.044

47. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119:3070-3077. doi:10.1161/CIRCULATIONAHA.108.815944

CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING
This research was funded by the Basic Science Research Program, through a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) [2018R1A2B6003972].

AUTHORS’ CONTRIBUTIONS
Conceptualization, methodology, data analysis, draft preparation, and final manuscript editing: YS and HL.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.